Q32 Bio (QTTB) EBIT Growth (1y) (2018 - 2026)
Q32 Bio (QTTB) EBIT Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 2,150.96% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 145.20% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Q32 Bio | 225.00 Mn | 174.25 Mn | - | 36.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.85% |
| Dec 31, 2025 | 415.84% |
| Sep 30, 2025 | 59.73% |
| Jun 30, 2025 | 48.82% |
| Mar 31, 2025 | 17.62% |
| Dec 31, 2024 | 43.72% |
| Sep 30, 2024 | -141.27% |
| Jun 30, 2024 | -146.31% |
| Mar 31, 2024 | -101.32% |
| Dec 31, 2023 | 25.18% |
| Sep 30, 2023 | 76.27% |
| Jun 30, 2023 | 74.30% |
| Mar 31, 2023 | 80.40% |
| Dec 31, 2022 | -2.58% |
| Sep 30, 2022 | -7.18% |
| Jun 30, 2022 | 7.35% |
| Mar 31, 2022 | -3,285.96% |
| Dec 31, 2021 | -12.83% |
| Sep 30, 2021 | -8.45% |
| Jun 30, 2021 | 14.41% |